Earnings Release • Oct 22, 2021
Earnings Release
Open in ViewerOpens in native device viewer


| SEKm | 2109 | 2009 | % | 2021:3 | 2020:3 | % |
|---|---|---|---|---|---|---|
| Net sales | 87,641 | 90,796 | -3 | 31,145 | 28,677 | 9 |
| Adjusted operating profit before amortization of acquisition related intangible assets (EBITA)1 |
10,603 | 13,234 | -20 | 3,586 | 4,119 | -13 |
| Operating profit before amortization of acquisition-related intangible assets (EBITA) |
11,047 | 13,177 | -16 | 4,110 | 4,018 | 2 |
| Amortization of acquisition-related intangible assets | -602 | -610 | -235 | -201 | ||
| Adjusted operating profit1 | 10,001 | 12,624 | -21 | 3,351 | 3,918 | -14 |
| Items affecting comparability | 444 | -57 | 524 | -101 | ||
| Operating profit | 10,445 | 12,567 | -17 | 3,875 | 3,817 | 2 |
| Financial items | -472 | -786 | -137 | -184 | ||
| Profit before tax | 9,973 | 11,781 | -15 | 3,738 | 3,633 | 3 |
| Adjusted Profit before tax1 | 9,529 | 11,838 | -20 | 3,214 | 3,734 | -14 |
| Income taxes | -2,381 | -3,063 | -773 | -1,033 | ||
| Profit for the period | 7,592 | 8,718 | -13 | 2,965 | 2,600 | 14 |
| Earnings per share, SEK | 9.45 | 10.80 | 3.90 | 3.22 | ||
| Adjusted earnings per share, SEK2 | 9.36 | 11.50 | 3.33 | 3.55 | ||
1Excluding items affecting comparability; for amounts see page 12.
2Excluding items affecting comparability and amortization of acquisition-related intangible assets.

Sales growth was strong in the third quarter and organic net sales rose 7.4% compared with the corresponding period a year ago, of which volume accounted for 4.2% and price/mix for 3.2%. Sales growth, including organic sales growth and acquisitions, amounted to 9.7%. Sales were positively impacted by more favorable market conditions and growing awareness of the importance of hygiene and health. Essity's organic net sales increased 1.9% compared with the third quarter of 2019. Personal Care and Professional Hygiene noted highly favorable organic sales growth during the third quarter of 2021 compared with the third quarter of 2020. Medical Solutions demonstrated strong growth and organic net sales rose 9.7%, with good growth in all product segments.
Organic net sales in mature markets increased 5.9%. In emerging markets, which accounted for 36% of net sales, organic net sales increased 10.2%.
During the quarter Essity has:
After the end of the quarter Essity has:
• Decided on new business areas from January 1, 2022. The business areas will be Health & Medical, Consumer Goods and Professional Hygiene. As a consequence of its higher growth ambitions, Essity has also decided on a new sales growth target of more than 5%, which includes both organic sales growth and acquisitions.
The Group's adjusted gross margin for the third quarter of 2021 decreased by 3.7 percentage points year on year to 28.7%. The gross margin was positively impacted by higher volumes, higher prices, an improved mix and cost savings. Higher raw material, energy and distribution costs reduced the margin by 6.7 percentage points. The Group's adjusted EBITA margin decreased 2.9 percentage points to 11.5%. Sales costs, excluding marketing costs, decreased in absolute terms and as a share of net sales. Investments in growth increased marketing costs in absolute terms but decreased as a share of net sales. Adjusted EBITA, excluding exchange rate effects, decreased 11%. The adjusted return on capital employed was 12.3%. Earnings per share increased 21% to SEK 3.90.

| SEKm | 2109 | 2009 | % | 2021:3 | 2020:3 | % |
|---|---|---|---|---|---|---|
| Net sales | 87,641 | 90,796 | -3 | 31,145 | 28,677 | 9 |
| Cost of goods sold1 | -61,011 | -61,312 | -22,202 | -19,389 | ||
| Adjusted gross profit1 | 26,630 | 29,484 | -10 | 8,943 | 9,288 | -4 |
| Sales, general and administration1 | -16,027 | -16,250 | -5,357 | -5,169 | ||
| Adjusted operating profit before amortization of acquisition-related intangible assets (EBITA)1 |
10,603 | 13,234 | -20 | 3,586 | 4,119 | -13 |
| Amortization of acquisition-related intangible assets | -602 | -610 | -235 | -201 | ||
| Adjusted operating profit1 | 10,001 | 12,624 | -21 | 3,351 | 3,918 | -14 |
| Financial items | -472 | -786 | -137 | -184 | ||
| Adjusted profit before tax1 | 9,529 | 11,838 | -20 | 3,214 | 3,734 | -14 |
| Adjusted Income taxes1 | -2,430 | -3,061 | -808 | -1,049 | ||
| Adjusted profit for the period1 1 Excluding items affecting comparability; for amounts see page 12. |
7,099 | 8,777 | -19 | 2,406 | 2,685 | -10 |
| Adjusted Margins (%) | ||||||
| Gross margin1 | 30.4 | 32.5 | 28.7 | 32.4 | ||
| EBITA margin1 | 12.1 | 14.6 | 11.5 | 14.4 | ||
| Operating margin1 | 11.4 | 13.9 | 10.8 | 13.7 | ||
| Financial net margin | -0.5 | -0.9 | -0.4 | -0.6 | ||
| Profit margin1 | 10.9 | 13.0 | 10.4 | 13.1 | ||
| Income taxes1 | -2.8 | -3.4 | -2.6 | -3.7 | ||
| Net margin1 | 8.1 | 9.6 | 7.8 | 9.4 |
1Excluding items affecting comparability; for amounts see page 12.
| 2109 | 2009 | % | 2021:3 | 2020:3 | % |
|---|---|---|---|---|---|
| 5,332 | 5,282 | 1 | 1,914 | 1,805 | 6 |
| 3,834 | 6,110 | -37 | 942 | 1,894 | -50 |
| 2,029 | 2,508 | -19 | 900 | 634 | 42 |
| -592 | -666 | -170 | -214 | ||
| 10,603 | 13,234 | -20 | 3,586 | 4,119 | -13 |
1Excluding items affecting comparability; for amounts see page 12.
| SEKm | 2109 | 2009 | % | 2021:3 | 2020:3 | % |
|---|---|---|---|---|---|---|
| Personal Care | 4,741 | 4,705 | 1 | 1,682 | 1,614 | 4 |
| Consumer Tissue | 3,830 | 6,106 | -37 | 941 | 1,894 | -50 |
| Professional Hygiene | 2,022 | 2,479 | -18 | 898 | 624 | 44 |
| Other | -592 | -666 | -170 | -214 | ||
| Total1 | 10,001 | 12,624 | -21 | 3,351 | 3,918 | -14 |
1Excluding items affecting comparability; for amounts see page 12.
| SEKm | 2109 | 2009 | % | 2021:3 | 2020:3 | % |
|---|---|---|---|---|---|---|
| Personal Care | 4,939 | 5,352 | -8 | 2,318 | 2,016 | 15 |
| Consumer Tissue | 2,379 | 5,037 | -53 | 629 | 515 | 22 |
| Professional Hygiene | 1,758 | 2,414 | -27 | 1,132 | 783 | 45 |
| Other | -1,164 | -907 | -403 | -245 | ||
| Total | 7,912 | 11,896 | -33 | 3,676 | 3,069 | 20 |


Excluding items affecting comparability
| 2109 vs 2009 |
21:3 vs 20:3 |
|
|---|---|---|
| Total | -3.5 | 8.6 |
| Volume | 1.1 | 4.2 |
| Price/mix | 0.5 | 3.2 |
| Currency | -5.1 | -0.2 |
| Acquisitions | 0.8 | 2.3 |
| Divestments | -0.8 | -0.9 |
| 2109 vs | 21:3 vs | ||
|---|---|---|---|
| 2009 | 20:3 | ||
| Total | -20 | -13 | |
| Volume | 4 | 12 | |
| Price/mix | 3 | 20 | |
| Raw materials | -13 | -37 | |
| Energy | -4 | -8 | |
| Currency | -6 | -2 | |
| Other | -4 | 2 |
-

Excluding items affecting comparability

Net sales declined 3.5% compared with the corresponding period a year ago to SEK 87,641m (90,796). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 1.6%, of which volume accounted for 1.1% and price/mix for 0.5%. Sales were negatively impacted by the COVID-19 pandemic and the related lockdowns and restrictions, primarily within Professional Hygiene. Organic net sales declined 2.1% in mature markets and increased 8.2% in emerging markets. Emerging markets accounted for 38% of net sales. Exchange rate effects reduced net sales by 5.1%. The acquisition of Asaleo Care increased net sales by 0.8%. Divestments and deconsolidation reduced net sales by 0.8%.
The Group's adjusted gross margin decreased by 2.1 percentage points year on year to 30.4% (32.5). The gross margin was positively impacted by an improved mix, higher volumes and cost savings. Continuous cost savings amounted to SEK 470m. Higher costs for raw materials, energy and distribution, and lower prices in Consumer Tissue had a negative impact on the margin.
The Group's adjusted EBITA margin decreased 2.5 percentage points to 12.1% (14.6). Sales costs, excluding marketing costs, increased in absolute terms but was, as a share of net sales, in line with the corresponding period a year ago. Investments in growth increased marketing costs in absolute terms and as a share of net sales.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) decreased 20% (13% excluding currency translation effects, acquisitions and divestments) to SEK 10,603m (13,234).
Items affecting comparability amounted to SEK 444m (-57). Essity's previous holding of 36.2% in Asaleo Care was remeasured on July 1, yielding a positive revaluation effect of SEK 706m. Other costs are mainly related to transaction costs for the acquisitions of Asaleo Care and Productos Familia S.A., as well as restructuring costs.
Financial items decreased to SEK -472m (-786). Lower interest and lower average net debt had a positive impact.
Adjusted profit before tax decreased 20% (14% excluding currency translation effects, acquisitions and divestments) and amounted to SEK 9,529m (11,838).
The tax expense, excluding effects of items affecting comparability, was SEK 2,430m (3,061).
Adjusted profit for the period decreased 19% (13% excluding currency translation effects, acquisitions and divestments) to SEK 7,099m (8,777).
Profit for the period decreased 13% (7% excluding currency translation effects, acquisitions and divestments) to SEK 7,592m (8,718). Earnings per share were SEK 9.45 (10.80). The adjusted earnings per share were SEK 9.36 (11.50).
The adjusted return on capital employed was 13.4% (15.7). The adjusted return on equity was 15.6% (18.5).
Net sales increased 8.6% compared with the corresponding period a year ago to SEK 31,145m (28,677). Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 7.4%, of which volume accounted for 4.2% and price/mix for 3.2%. Essity's organic net sales increased 1.9% compared with the third quarter of 2019. Personal Care and Professional Hygiene noted highly favorable organic sales growth in the third quarter of 2021 compared with the third quarter of 2020. Medical Solutions noted strong growth and organic net sales rose by 9.7% with good growth in all product segments. Organic net sales increased 5.9% in mature markets and increased 10.2% in emerging markets. Emerging markets accounted for 36% of net sales. Exchange rate effects reduced net sales by 0.2%. The acquisition of Asaleo Care increased net sales by 2.3%. Divestments and deconsolidation reduced net sales by 0.9%.
The Group's adjusted gross margin for the third quarter of 2021 decreased by 3.7 percentage points year on year to 28.7% (32.4). The gross margin was positively impacted by higher volumes, higher prices, an improved mix and cost savings. The continuous costs savings

amounted to SEK 219m. Higher raw material, energy and distribution costs reduced the margin by 6.7 percentage points. The Group's adjusted EBITA margin decreased 2.9 percentage points to 11.5% (14.4). Sales costs, excluding marketing costs, decreased in absolute terms and as a share of net sales. Investments in growth increased marketing costs in absolute terms but decreased as a share of net sales.
Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) decreased 13% (13% excluding currency translation effects, acquisitions and divestments) to SEK 3,586m (4,119).
Adjusted profit before tax decreased 14% (14% excluding currency translation effects, acquisitions and divestments) and amounted to SEK 3,214m (3,734).
Profit for the period increased 14% (14% excluding currency translation effects, acquisitions and divestments) to SEK 2,965m (2,600). Earnings per share were SEK 3.90 (3.22). The adjusted earnings per share were SEK 3.33 (3.55).
The adjusted return on capital employed was 12.3% (14.7). The adjusted return on equity was 14.6% (16.5).
January–September 2021 compared with the corresponding period a year ago The operating cash surplus amounted to SEK 15,598m (18,469). The cash flow effect of changes in working capital was SEK -1,858m (-1,713). Working capital was negatively impacted by an increase in trade receivables as a result of higher sales and increased inventory value on account of rising raw material prices. Investments in non-current assets, net, excluding investments in operating assets through leases, amounted to SEK -5,195m (-3,975). Operating cash flow before investments in operating assets through leases amounted to SEK 8,000m (12,111). Investments in operating assets through leases amounted to SEK -88m (-215). Operating cash flow was SEK 7,912m (11,896).
Financial items decreased to SEK -472m (-786). Lower interest and lower average net debt had a positive impact.
Tax payments had an impact on cash flow of SEK -2,768m (-2,581).
The net sum of acquisitions and divestments was SEK -10,555m (-749). Net cash flow totaled SEK -11,084m (7,513).
Net debt increased SEK 12,863m during the period and amounted to SEK 55,551m. Excluding pension liabilities, net debt amounted to SEK 53,031m. Net cash flow increased net debt by SEK 11,084m. Fair value measurement of pension assets and updated assumptions and assessments that affect measurement of the net pension liability, together with fair value measurement of financial instruments, increased net debt by SEK 43m. Exchange rate movements increased net debt by SEK 1,415m. Investments in non-operating assets through leases increased net debt by SEK 321m. The debt/equity ratio was 0.85 (0.69). Excluding pension liabilities, the debt/equity ratio was 0.81 (0.62). The debt payment capacity was 31% (45). Net debt in relation to adjusted EBITDA amounted to 2.60 (1.85).
The Group's equity increased by SEK 2,027m during the period, to SEK 65,369m. Net profit for the period increased equity by SEK 7,592m. Equity decreased due to dividends to shareholders of SEK 5,253m. Equity increased net after tax by SEK 77m as a result of fair value measurement of pension assets and updated assumptions and assessments that affect the valuation of the pension liability. Fair value measurement of financial instruments increased equity by SEK 2,430m after tax. Exchange rate movements, including the effect of hedges of net foreign investments, after tax, increased equity by SEK 3,108m. Equity decreased by SEK 5,960m due to the acquisition of the non-controlling interest in Productos Familia S.A. Other items increased equity by SEK 33m.

A tax expense of SEK 2,430m was reported, excluding items affecting comparability, corresponding to a tax rate of 25.5% for the period. The tax expense including items affecting comparability was SEK 2,381m, corresponding to a tax rate of 23.9% for the period.
On July 1, 2021, Essity announced that it had finalized its acquisition of Australian hygiene company Asaleo Care. The new regional unit, Essity AustralAsia, was consolidated into Essity's accounts as of July 1, 2021.
On July 6, 2021, Essity announced that the company is investing approximately EUR 11m (approximately SEK 110m) in its Hondouville tissue mill in France. The investment will allow the extraction of 98% of paper fibers contained in food and beverage cartons, enabling Essity to achieve a recycling capacity of 24,000 tons of carton a year. The fibers from these cartons are used in the fiber mix to manufacture Tork-branded products within the business area Professional Hygiene.
On July 16, 2021, Essity announced new and updated sustainability targets including a commitment to develop targets to reach net-zero greenhouse gas emissions by 2050 at the latest. This includes raising the ambition level of Essity's current Science Based Targets. Other updated targets include sustainable innovations, occupational safety and responsible sourcing.
On August 31, 2021, Essity announced that the company had finalized its acquisition of 45.8% of the shares in Colombian hygiene company Productos Familia S.A. ("Familia"). Essity now owns 95.8% of Familia. The purchase price amounts to USD 1,540m (approximately SEK 13bn) for 100% of the company on a debt-free basis. The acquisition is expected to be accretive to Essity's earnings per share from 2021.
On September 8, 2021, Essity announced that the company had raised EUR 600m in the bond market under its Euro Medium Term Note (EMTN) program. The re-offer yield for the bond was 0.33% with a maturity date of September 15, 2029, corresponding to mid swaps +0.43 percentage points. The purpose of the issue is to refinance maturing loans and to finance operations.
On September 30, 2021, Essity announced that the company had made a breakthrough in sustainable tissue production and is beginning production based on pulp from wheat straw. The plant in Mannheim, Germany, is the first of its kind in Europe, and the first for large-scale tissue production in the world.
On October 6, 2021, Essity announced that the company is investing approximately SEK 95m in enhanced efficiency in the company's site in Kawerau, New Zealand, including the world's first tissue machine running a fully geothermal steam drying process. Together with a reduction in pulp consumption, reduced waste and elimination of the burning of natural gas on the machine, the improvements will contribute to a reduction of carbon emissions by 23 percent from the Kawerau site.
On October 22, 2021, Essity announced that the company decided on new business areas from January 1, 2022. The business areas will be Health & Medical, Consumer Goods and Professional Hygiene. As a consequence of its higher growth ambitions, Essity has also decided on a new sales growth target of more than 5%, which includes both organic sales growth and acquisitions.

The new Health & Medical, Consumer Goods and Professional Hygiene business areas will apply as of January 1, 2022. These are aligned with the company's customer and sales channels and will lead to an expansion of the offerings to new and adjacent categories as well as extended service content on the basis of customer and consumer needs. The new areas support the company's new growth target through strategies for organic and acquisition-driven growth and aim to achieve higher growth and profit margins as well as less capital tied up. The business areas will replace the current business areas Personal Care, Consumer Tissue and Professional Hygiene.
The new growth target is to achieve sales growth of more than 5%. This replaces the previous target of organic sales growth of more than 3%. The target will be reached through the continued implementation of Essity's strategy: leveraging favorable market trends, increasing market shares through successful innovation and strong brands, expanding the offering and acquisitions in categories with high margins. Growth, both organic and through acquisitions, is prioritized in the Medical Solutions, Incontinence Products, Feminine Care and Professional Hygiene product categories.
Financial reporting for the new business areas, Proforma for the first nine months 2021
| SEKm | Health & Medical |
Consumer Goods |
Professional Hygiene |
Other | Essity |
|---|---|---|---|---|---|
| Net sales | 15,831 | 53,196 | 18,616 | -2 | 87,641 |
| Adjusted EBITA1) | 2,893 | 6,273 | 2,029 | -592 | 10,603 |
| Adjusted EBITA margin1), % | 18.3% | 11.8% | 10.9% | 12.1% |
1) Excluding items affecting comparability




| 2109 vs 2009 |
21:3 vs 20:3 |
|
|---|---|---|
| Total | -1.2 | 9.0 |
| Volume | 2.7 | 5.8 |
| Price/mix | 1.8 | 2.7 |
| Currency | -5.7 | -0.9 |
| Acquisitions | 1.0 | 2.4 |
| Divestments | -1.0 | -1.0 |
| 2109 vs 2009 |
21:3 vs 20:3 |
|
|---|---|---|
| Total | 1 | 6 |
| Volume | 9 | 18 |
| Price/mix | 10 | 16 |
| Raw materials | -11 | -28 |
| Energy | -1 | -1 |
| Currency | -8 | -3 |
| Other | 2 | 4 |
| SEKm | 2109 | 2009 | % | 2021:3 | 2020:3 | % |
|---|---|---|---|---|---|---|
| Net sales | 34,034 | 34,435 | -1 | 12,112 | 11,115 | 9 |
| Adjusted gross profit margin, %* | 41.2 | 41.1 | 40.0 | 41.8 | ||
| Adjusted EBITA* | 5,332 | 5,282 | 1 | 1,914 | 1,805 | 6 |
| Adjusted EBITA margin, %* | 15.7 | 15.3 | 15.8 | 16.2 | ||
| Adjusted operating profit* | 4,741 | 4,705 | 1 | 1,682 | 1,614 | 4 |
| Adjusted operating margin, %* | 13.9 | 13.7 | 13.9 | 14.5 | ||
| Adjusted return on capital employed, %* | 16.9 | 15.8 | 17.5 | 16.5 | ||
| Operating cash flow | 4,939 | 5,352 | 2,318 | 2,016 |
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales declined 1.2% to SEK 34,034m (34,435). Organic net sales increased 4.5%, of which volume accounted for 2.7% and price/mix for 1.8%. Organic net sales in mature markets increased 2.4%. In emerging markets, which accounted for 35% of net sales, organic net sales increased 8.3%. Exchange rate effects reduced net sales by 5.7%. The acquisition of Asaleo Care increased net sales by 1.0%. Divestments reduced net sales by 1.0%.
For Incontinence Products, with Essity's globally leading TENA brand, organic net sales increased 2.5%. In Medical Solutions, organic net sales increased 12.2%. For Baby Care, organic net sales declined 0.4%. For Feminine Care, organic net sales increased 8.3%.
The adjusted gross margin increased 0.1 of a percentage point to 41.2% (41.1). The gross margin was positively impacted by higher volumes, higher prices, an improved mix and cost savings. Higher costs for raw materials and distribution had a negative impact on the margin. The adjusted EBITA margin increased 0.4 of a percentage point to 15.7% (15.3). Sales costs, excluding marketing costs, were in absolute terms in line with the corresponding period a year ago but decreased as a share of net sales. Investments in growth increased marketing costs in absolute terms and as a share of net sales. Adjusted EBITA increased 1% (8% excluding currency translation effects, acquisitions and divestments) to SEK 5,332m (5,282).
The operating cash surplus amounted to SEK 6,644m (6,715).
Net sales increased 9.0% to SEK 12,112m (11,115). Organic net sales increased 8.5%, of which volume accounted for 5.8% and price/mix for 2.7%. Organic net sales in mature markets increased 5.2%. In emerging markets, which accounted for 35% of net sales, organic net sales increased 15.0%. Exchange rate effects reduced net sales by 0.9%. The acquisition of Asaleo Care increased net sales by 2.4%. Divestments reduced net sales by 1.0%.
For Incontinence Products, with Essity's globally leading TENA brand, organic net sales increased 8.4%. The increase was attributable to Europe, North America and emerging markets. In Medical Solutions, organic net sales increased 9.7% and all product categories demonstrated healthy sales growth. For Baby Care, organic net sales increased 1.5%, primarily related to western Europe and Latin America. For Feminine Care, organic net sales increased 15.8% related to Europe, Latin America and Asia.
-6 The adjusted gross margin decreased 1.8 percentage points to 40.0% (41.8). The gross margin was positively impacted by higher volumes, higher prices, an improved mix and cost savings. Higher raw material and distribution costs had a negative impact on the margin. The adjusted EBITA margin decreased 0.4 of a percentage point to 15.8% (16.2). Sales costs, excluding marketing costs, increased in absolute terms but decreased as a share of net sales. Investments in growth increased marketing costs in absolute terms but decreased as a share of net sales. Adjusted EBITA increased 6% (6% excluding currency translation effects, acquisitions and divestments) to
SEK 1,914m (1,805).






Change in net sales (%)
| 2109vs 2009 |
21:3 vs 20:3 |
|
|---|---|---|
| Total | -5.8 | 1.2 |
| Volume | 0.2 | -3.0 |
| Price/mix | -1.5 | 2.4 |
| Currency | -4.0 | 1.3 |
| Acquisitions | 0.5 | 1.6 |
| Divestments | -1.0 | -1.1 |
| 2109 vs 2009 |
21:3 vs 20:3 |
|
|---|---|---|
| Total | -37 | -50 |
| Volume | 2 | -5 |
| Price/mix | -10 | 14 |
| Raw materials | -10 | -37 |
| Energy | -6 | -12 |
| Currency | -4 | 1 |
| Other | -9 | -11 |
| SEKm | 2109 | 2009 | % | 2021:3 | 2020:3 | % |
|---|---|---|---|---|---|---|
| Net sales | 34,993 | 37,151 | -6 | 11,770 | 11,634 | 1 |
| Adjusted gross profit margin, %* | 23.0 | 27.4 | 20.0 | 27.6 | ||
| Adjusted EBITA* | 3,834 | 6,110 | -37 | 942 | 1,894 | -50 |
| Adjusted EBITA margin, %* | 11.0 | 16.4 | 8.0 | 16.3 | ||
| Adjusted operating profit* | 3,830 | 6,106 | -37 | 941 | 1,894 | -50 |
| Adjusted operating margin, %* | 10.9 | 16.4 | 8.0 | 16.3 | ||
| Adjusted return on capital employed, %* | 12.1 | 16.7 | 7.6 | 16.5 | ||
| Operating cash flow | 2,379 | 5,037 | 629 | 515 |
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales decreased 5.8% to SEK 34,993m (37,151). Organic net sales decreased 1.3%. Volumes accounted for an increase of 0.2% and the price/mix a decrease of 1.5%. Organic net sales decreased 8.3% in mature markets. In emerging markets, which accounted for 49% of net sales, organic net sales increased by 7.0%. Exchange rate effects decreased net sales by 4.0%. The acquisition of Asaleo Care increased net sales by 0.5%. Divestments and deconsolidation decreased net sales by 1.0%.
The adjusted gross margin decreased by 4.4 percentage points to 23.0% (27.4). The gross margin was positively impacted by higher volumes, an improved mix and cost savings. Higher raw material, energy and distribution costs and lower prices had a negative impact on the margin. The adjusted EBITA margin decreased 5.4 percentage points to 11.0% (16.4). Sales and marketing costs increased in absolute terms and as a share of net sales. Adjusted EBITA decreased 37% (34% excluding currency translation effects, acquisitions and divestments) to SEK 3,834m (6,110).
The operating cash surplus totaled SEK 5,837m (8,189).
Net sales increased 1.2% to SEK 11,770m (11,634). Organic net sales decreased 0.6%. Volumes accounted for a decrease of 3.0% and the price/mix an increase of 2.4%. Organic net sales decreased 4.7% in mature markets. In emerging markets, which accounted for 48% of net sales, organic net sales increased by 4.5%. Exchange rate effects increased net sales by 1.3%. The acquisition of Asaleo Care increased net sales by 1.6%. Divestments and deconsolidation decreased net sales by 1.1%.
The adjusted gross margin decreased by 7.6 percentage points to 20.0% (27.6). The gross margin was positively impacted by higher prices, an improved mix and cost savings. Higher raw material and energy costs reduced the margin by 8.1 percentage points. Lower volumes and higher distribution costs had a negative impact on the margin. The adjusted EBITA margin decreased 8.3 percentage points to 8.0% (16.3). Sales and marketing costs increased in absolute terms and as a share of net sales. Adjusted EBITA decreased 50% (52% excluding currency translation effects, acquisitions and divestments) to SEK 942m (1,894).
-6






Change in net sales (%)
| 2109 vs 2009 |
21:3 vs 20:3 |
||
|---|---|---|---|
| Total | -3.1 | 22.4 | |
| Volume | 0.0 | 15.2 | |
| Price/mix | 2.2 | 5.5 | |
| Currency | -6.3 | -1.9 | |
| Acquisitions | 1.1 | 3.6 | |
| Divestments | -0.1 | 0.0 |
| 2109 vs 2009 |
21:3 vs 20:3 |
|||
|---|---|---|---|---|
| Total | -19 | 42 | ||
| Volume | -3 | 46 | ||
| Price/mix | 19 | 43 | ||
| Raw materials | -18 | -51 | ||
| Energy | -5 | -11 | ||
| Currency | -6 | -6 | ||
| Other | -6 | 21 | ||
| 2109 | 2009 | % | 2021:3 | 2020:3 | % |
|---|---|---|---|---|---|
| 18,616 | 19,202 | -3 | 7,260 | 5,930 | 22 |
| 24.5 | 26.9 | 24.0 | 24.1 | ||
| 2,029 | 2,508 | -19 | 900 | 634 | 42 |
| 10.9 | 13.1 | 12.4 | 10.7 | ||
| 2,022 | 2,479 | -18 | 898 | 624 | 44 |
| 10.9 | 12.9 | 12.4 | 10.5 | ||
| 12.6 | 16.7 | 15.3 | 11.2 | ||
| 1,758 | 2,414 | 1,132 | 783 | ||
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales declined 3.1% to SEK 18,616m (19,202). Organic net sales increased 2.2%, of which volume accounted for 0.0% and price/mix for 2.2%. Organic net sales declined 0.5% in mature markets. In emerging markets, which accounted for 21% of net sales, organic net sales increased by 13.8%. Exchange rate effects reduced net sales by 6.3%. The acquisition of Asaleo Care increased net sales by 1.1%. Divestments decreased net sales by 0.1%.
The adjusted gross margin decreased 2.4 percentage points to 24.5% (26.9). The gross margin was positively impacted by higher prices, an improved mix and cost savings. Higher raw material, energy and distribution costs had a negative impact on the margin. The adjusted EBITA margin decreased 2.2 percentage points to 10.9% (13.1). Sales and marketing costs decreased in absolute terms and as a share of net sales. Adjusted EBITA decreased 19% (13% excluding currency translation effects, acquisitions and divestments) to SEK 2,029m (2,508).
The operating cash surplus was SEK 3,549m (4,123).
Net sales increased 22.4% to SEK 7,260m (5,930). Organic net sales, which excludes currency effects, acquisitions and divestments, increased 20.7%. Volumes accounted for an increase of 15.2% and price/mix of 5.5%. The negative effect of the COVID-19 pandemic and the related lockdowns and restrictions were lower in the third quarter of 2021 compared with the preceding year. Organic net sales increased 20.8% in mature markets. In emerging markets, which accounted for 20% of net sales, organic net sales increased by 20.6%. Exchange rate effects reduced net sales by 1.9%. The acquisition of Asaleo Care increased net sales by 3.6%.
The adjusted gross margin declined 0.1 of a percentage point to 24.0% (24.1). The gross margin was positively impacted by higher volumes, higher prices, an improved mix and cost savings. Higher raw material, energy and distribution costs had a negative impact on the margin. The adjusted EBITA margin increased 1.7 percentage points to 12.4% (10.7). Sales and marketing costs decreased in absolute terms and as a share of net sales. Adjusted EBITA increased 42% (48% excluding currency translation effects, acquisitions and divestments) to SEK 900m (634).
-6

| September 30, 2021 | Class A | Class B | Total |
|---|---|---|---|
| Registered number of shares | 61,667,918 | 640,674,571 | 702,342,489 |
At the end of the period, the proportion of Class A shares was 8.8%. During the third quarter, 66,454 Class A shares were converted into Class B shares at the request of shareholders. The total number of votes in the company amounts to 1,257,353,751.
The Year-end Report for 2021 will be published on January 26, 2022. Essity's Annual Report for 2021 will be published during the week starting February 28, 2022. In 2022, interim reports will be published on April 28, July 21 and October 27.
Essity will arrange a capital markets day on November 3, 2021.
Essity's Annual General Meeting will be held in Stockholm on March 24, 2022.
In conjunction with publication, a telephone and web presentation will be held where President and CEO Magnus Groth will present the report and answer questions.
Date: Friday, October 22, 2021 Time: 9:00 a.m. CET Link to web presentation: https://essity.videosync.fi/2021-10-22-q3 To participate by telephone, call: +44 (0)207 192 80 00, +1 631 510 74 95 or +46 (0)8 506 921 80. Please call well in advance of the start of the presentation. Specify "Essity" or conference ID no. 9798955.
Stockholm, October 22, 2021 Essity Aktiebolag (publ)
Magnus Groth President and CEO
Fredrik Rystedt, CFO and Executive Vice President, +46 (0)8 788 51 31 Johan Karlsson, Vice President Investor Relations, Group Function Communications, +46 (0)8 788 51 30 Joséphine Edwall Björklund, Senior Vice President, Group Function Communications, +46 (0)8 788 52 34 Per Lorentz, Vice President Corporate Communications, Group Function Communications, +46 (0)8 788 52 51
This report has not been reviewed by the company's auditors.
This information is such information that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of the contact person set out below, at 7:00 a.m. CET on October 22, 2021.
Karl Stoltz, Media Relations Manager, +46 (0)8 788 51 55

| SEKm | 2021:3 | 2020:3 | 2021:2 | 2109 | 2009 |
|---|---|---|---|---|---|
| Net sales | 31,145 | 28,677 | 28,968 | 87,641 | 90,796 |
| Cost of goods sold1,2 | -22,202 | -19,389 | -20,149 | -61,011 | -61,312 |
| Items affecting comparability - cost of goods sold2 | -11 | -94 | -43 | -64 | -203 |
| Gross profit | 8,932 | 9,194 | 8,776 | 26,566 | 29,281 |
| Sales, general and administration1,2 | -5,361 | -5,181 | -5,446 | -16,079 | -16,311 |
| Items affecting comparability - sales, general and administration2 | 535 | -7 | -93 | 508 | 146 |
| Share of profits of associated and joint ventures | 4 | 12 | 36 | 52 | 61 |
| Operating profit before amortization of acquisition-related intangible assets (EBITA) |
4,110 | 4,018 | 3,273 | 11,047 | 13,177 |
| Amortization of acquisition-related intangible assets | -235 | -201 | -181 | -602 | -610 |
| Operating profit | 3,875 | 3,817 | 3,092 | 10,445 | 12,567 |
| Financial items | -137 | -184 | -177 | -472 | -786 |
| Profit before tax | 3,738 | 3,633 | 2,915 | 9,973 | 11,781 |
| Income taxes | -773 | -1,033 | -840 | -2,381 | -3,063 |
| Profit for the period | 2,965 | 2,600 | 2,075 | 7,592 | 8,718 |
| Earnings attributable to: | |||||
| Owners of the Parent company | 2,736 | 2,265 | 1,770 | 6,638 | 7,588 |
| Non-controlling interests | 229 | 335 | 305 | 954 | 1,130 |
| Earnings per share - owners of the Parent company | |||||
| Earnings per share before and after dilution effects, SEK | 3.90 | 3.22 | 2.52 | 9.45 | 10.80 |
| Average numbers of shares before and after dilution, million | 702.3 | 702.3 | 702.3 | 702.3 | 702.3 |
| 1Of which, depreciation and amortization | -1,857 | -1,773 | -1,725 | -5,288 | -5,514 |
| 2Of which, impairment | -75 | -141 | -26 | -102 | -257 |
| Gross margin | 28.7 | 32.1 | 30.3 | 30.3 | 32.2 |
| EBITA margin | 13.2 | 14.0 | 11.3 | 12.6 | 14.5 |
| Operating margin | 12.4 | 13.3 | 10.7 | 11.9 | 13.8 |
| Financial net margin | -0.4 | -0.6 | -0.6 | -0.5 | -0.9 |
| Profit margin Income taxes |
12.0 -2.5 |
12.7 -3.6 |
10.1 -2.9 |
11.4 -2.7 |
12.9 -3.4 |
| Net margin | 9.5 | 9.1 | 7.2 | 8.7 | 9.5 |
| Excluding items affecting comparability: Gross margin |
28.7 | 32.4 | 30.4 | 30.4 | 32.5 |
| EBITA margin | 11.5 | 14.4 | 11.8 | 12.1 | 14.6 |
| Operating margin | 10.8 | 13.7 | 11.1 | 11.4 | 13.9 |
| Financial net margin | -0.4 | -0.6 | -0.6 | -0.5 | -0.9 |
| Profit margin | 10.4 | 13.1 | 10.5 | 10.9 | 13.0 |
| Income taxes | -2.6 | -3.7 | -2.9 | -2.8 | -3.4 |
| Net margin | 7.8 | 9.4 | 7.6 | 8.1 | 9.6 |

| SEKm | 2021:3 | 2020:3 | 2021:2 | 2109 | 2009 |
|---|---|---|---|---|---|
| Profit for the period | 2,965 | 2,600 | 2,075 | 7,592 | 8,718 |
| Other comprehensive income for the period | |||||
| Items that will not be reclassified to the income statement | |||||
| Actuarial gains/losses on defined benefit pension plans | -1,141 | 388 | 761 | -43 | -2,733 |
| Fair value through other comprehensive income | 0 | 2 | 1 | 1 | 0 |
| Income tax attributable to components in other comprehensive income | 258 | -85 | 54 | 119 | 576 |
| -883 | 305 | 816 | 77 | -2,157 | |
| Items that have been or may be reclassified subsequently to the income statement | |||||
| Cash flow hedges | |||||
| Result from remeasurement of derivatives recognized in equity | 2,795 | 74 | 772 | 3,762 | -218 |
| Transferred to profit or loss for the period | -321 | 130 | -93 | -467 | 427 |
| Translation differences in foreign operations | 1,448 | -1,518 | -925 | 3,728 | -3,584 |
| Gains/losses from hedges of net investments in foreign operations | -291 | 367 | 223 | -758 | 443 |
| Other comprehensive income from associated companies | 0 | -2 | 11 | 12 | -12 |
| Income tax attributable to components in other comprehensive income | -600 | -127 | -237 | -731 | -132 |
| 3,031 | -1,076 | -249 | 5,546 | -3,076 | |
| Other comprehensive income for the period, net of tax | 2,148 | -771 | 567 | 5,623 | -5,233 |
| Total comprehensive income for the period | 5,113 | 1,829 | 2,642 | 13,215 | 3,485 |
| Total comprehensive income attributable to: | |||||
| Owners of the Parent company | 4,610 | 1,613 | 2,496 | 11,722 | 2,759 |
| Non-controlling interests | 503 | 216 | 146 | 1,493 | 726 |
| SEKm | 2109 | 2009 |
|---|---|---|
| Equity attributable to owners of the Parent company | ||
| Value, January 1 | 54,352 | 54,125 |
| Total comprehensive income for the period | 11,722 | 2,759 |
| Dividend | -4,741 | 0 |
| Acquisition of non-controlling interests | -4,041 | -1 |
| Private placement to non-controlling interests | 12 | 32 |
| Transferred to cost of hedged investments | 4 | -7 |
| Revaluation effect upon acquisition of non-controlling interests | -3 | -1 |
| Value, March 31 | 57,305 | 56,907 |
| Non-controlling interests | ||
| Value, January 1 | 8,990 | 8,676 |
| Total comprehensive income for the period | 1,493 | 726 |
| Dividend | -512 | -436 |
| Private placement to non-controlling interests | 12 | 30 |
| Divestment of non-controlling interests | 0 | 35 |
| Acquisition of non-controlling interests | -1,919 | -1 |
| Value, March 31 | 8,064 | 9,030 |
| Total equity, value March 31 | 65,369 | 65,937 |

| SEKm | 2109 | 2009 |
|---|---|---|
| Operating cash surplus | 15,598 | 18,469 |
| Change in working capital | -1,858 | -1,713 |
| Investment in non current assets, net | -5,195 | -3,975 |
| Restructuring costs, etc. | -545 | -670 |
| Operating cash flow before Investments in operating assets through leases | 8,000 | 12,111 |
| Investments in operating assets through leases | -88 | -215 |
| Operating cash flow | 7,912 | 11,896 |
| Financial items | -472 | -786 |
| Income taxes paid | -2,768 | -2,581 |
| Other | 72 | 31 |
| Cash flow from current operations | 4,744 | 8,560 |
| Acquisitions of Group companies and other operations | -10,564 | -748 |
| Divestments of Group companies and other operations | 9 | -1 |
| Cash flow before transactions with shareholders | -5,811 | 7,811 |
| Private placement to non-controlling interests | 24 | 60 |
| Dividend to non-controlling interests | -556 | -358 |
| Dividend | -4,741 | 0 |
| Net cash flow | -11,084 | 7,513 |
| Net debt at the start of the period | -42,688 | -50,940 |
| Net cash flow | -11,084 | 7,513 |
| Remeasurements to equity | -43 | -2,733 |
| Investments in non-operating assets through leases | -321 | -331 |
| Translation differences | -1,415 | 797 |
| Net debt at the end of the period | -55,551 | -45,694 |
| Debt/equity ratio | 0.85 | 0.69 |
| Debt payment capacity, % | 31 | 45 |
| Net debt / EBITDA | 2.53 | 1.84 |
| Net debt / Adjusted EBITDA | 2.60 | 1.85 |

| SEKm | 2109 | 2009 |
|---|---|---|
| Operating activities | ||
| Operating profit | 10,445 | 12,567 |
| Adjustment for non-cash items1 | 5,060 | 5,914 |
| Interest paid | -580 | -725 |
| Interest received | 75 | 80 |
| Other financial items | -10 | -190 |
| Change in liabilities relating to restructuring programs, etc. | -380 | -840 |
| Paid tax | -2,768 | -2,581 |
| Cash flow from operating activities before changes in working capital | 11,842 | 14,225 |
| Cash flow from changes in working capital | ||
| Change in inventories | -2,175 | -2,734 |
| Change in operating receivables | -970 | -169 |
| Change in operating liabilities | 1,287 | 1,190 |
| Cash flow from operating activities | 9,984 | 12,512 |
| Investing activities | ||
| Acquisitions of Group companies and other operations | -3,188 | -668 |
| Divestments of Group companies and other operations | -7 | 0 |
| Investments in intangible assets and property, plant and equipment | -5,185 | -4,028 |
| Sale of property, plant and equipment | 34 | 65 |
| Loans granted to external parties | -112 | 0 |
| Repayment of loans from external parties | 0 | 22 |
| Paid interest capitalized in intangible asset and property, plant and equipment | -43 | -11 |
| Cash flow from investing activities | -8,501 | -4,620 |
| Financing activities | ||
| Private placement to non-controlling interests | 24 | 60 |
| Acquisition of non-controlling interests | -5,960 | 0 |
| Dividend | -4,741 | 0 |
| Proceeds from borrowings | 18,741 | 5,895 |
| Repayment of borrowings | -3,988 | -9,109 |
| Dividend to non-controlling interests | -556 | -358 |
| Cash flow from financing activities | 3,520 | -3,512 |
| Cash flow for the period | 5,003 | 4,380 |
| Cash and cash equivalents at the beginning of the period | 4,982 | 2,928 |
| Translation differences in cash and cash equivalents | 115 | -169 |
| Cash and cash equivalents at the end of the period | 10,100 | 7,139 |
| Cash flow from operating activities per share, SEK | 14.22 | 17.81 |
| Reconciliation with consolidated operating cash flow statement | ||
| Cash flow for the period | 5,003 | 4,380 |
| Repayment of loans from external parties | 0 | -22 |
| Repayment of borrowings | 3,988 | 9,109 |
| Proceeds from borrowings | -18,741 | -5,895 |
| Loans granted to external parties Impact from settlement of pension liability |
112 0 |
0 188 |
| Investment in operating assets through leases | -88 | -215 |
| Net debt in acquired and divested operations | -1,400 | -81 |
| Accrued interest | 43 | 49 |
| Other | -1 | 0 |
| Net cash flow according to consolidated operating cash flow statement | -11,084 | 7,513 |
| 1) Adjustment for non-cash items | ||
| Depreciation/amortization and impairment of non-current assets | 5,390 | 5,771 |
| Gain/loss on asset sales | -1 | -29 |
| Change in provision for ongoing competition case | -55 | 0 |
| Impact from settlement of pension liability | 0 | -188 |
| Gain/loss on divestments and liquidation | -8 | 8 |
| Non-cash items relating to efficiency program | -65 | -13 |
| Change, one-time foreign tax on non-current assets | -20 | 0 |
| Revaluation effect of previously owned holding upon acquisition | -706 | 0 |
| Other | 525 | 365 |
Total 5,060 5,914

| SEKm | September 30, 2021 | December 31, 2020 |
|---|---|---|
| ASSETS | ||
| Non-current assets | ||
| Goodwill | 36,481 | 32,324 |
| Other intangible assets | 20,749 | 18,574 |
| Property, plant and equipment | 57,142 | 53,631 |
| Participation in joint ventures and associates | 231 | 847 |
| Shares and participations | 7 | 7 |
| Surplus in funded pension plans | 1,763 | 2,817 |
| Non-current financial assets | 440 | 738 |
| Deferred tax assets | 1,970 | 1,823 |
| Other non-current assets | 1,393 | 768 |
| Total non-current assets | 120,176 | 111,529 |
| Current Assets | ||
| Inventories | 20,103 | 16,383 |
| Trade receivables | 19,126 | 17,825 |
| Current tax assets | 519 | 760 |
| Other current receivables | 5,614 | 2,173 |
| Current financial assets | 642 | 993 |
| Cash and cash equivalents | 10,100 | 4,982 |
| Total current assets | 56,104 | 43,116 |
| Total assets | 176,280 | 154,645 |
| EQUITY AND LIABILITIES | ||
| Equity | ||
| Share capital | 2,350 | 2,350 |
| Reserves | 5,578 | 581 |
| Retained earnings | 49,377 | 51,421 |
| Attributable to owner of the Parent | 57,305 | 54,352 |
| Non-controlling interests | 8,064 | 8,990 |
| Total equity | 65,369 | 63,342 |
| Non-current liabilities | ||
| Non-current financial liabilities | 49,193 | 38,202 |
| Provisions for pensions | 4,283 | 5,328 |
| Deferred tax liabilities | 7,647 | 6,150 |
| Other non-current provisions | 449 | 445 |
| Other non-current liabilities | 99 | 105 |
| Total non-current liabilities | 61,671 | 50,230 |
| Current liabilities | ||
| Current financial liabilities | 15,020 | 8,688 |
| Trade payables | 16,668 | 14,791 |
| Current tax liabilities | 1,537 | 2,301 |
| Current provisions | 630 | 748 |
| Other current liabilities | 15,385 | 14,545 |
| Total current liabilities | 49,240 | 41,073 |
| Total liabilities | 110,911 | 91,303 |
| Total equity and liabilities | 176,280 | 154,645 |

| SEKm | September 30, 2021 | December 31, 2020 |
|---|---|---|
| Debt/equity ratio | 0.85 | 0.67 |
| Equity/assets ratio | 33% | 35% |
| Equity | 65,369 | 63,342 |
| Equity per share, SEK | 93 | 90 |
| Return on equity | 16.3% | 18.2% |
| Return on equity excluding items affecting comparability | 15.6% | 18.3% |
| Capital employed | 120,920 | 106,030 |
| - of which working capital | 12,562 | 7,146 |
| Return on capital employed* | 13.8% | 15.6% |
| Return on capital employed* excluding items affecting comparability | 13.4% | 15.7% |
| Net debt | 55,551 | 42,688 |
| Provisions for restructuring costs are included in the balance sheet as follows | ||
| -Other non-current provisions | 108 | 137 |
| -Other current provisions | 135 | 263 |
*) rolling 12 months

| SEKm | 2109 | 2009 | 2021:3 | 2021:2 | 2021:1 | 2020:4 | 2020:3 | 2020:2 |
|---|---|---|---|---|---|---|---|---|
| Personal Care | 34,034 | 34,435 | 12,112 | 11,163 | 10,759 | 11,660 | 11,115 | 10,651 |
| Consumer Tissue | 34,993 | 37,151 | 11,770 | 11,669 | 11,554 | 13,070 | 11,634 | 12,437 |
| Professional Hygiene | 18,616 | 19,202 | 7,260 | 6,140 | 5,216 | 6,216 | 5,930 | 5,315 |
| Other | -2 | 8 | 3 | -4 | -1 | 10 | -2 | 4 |
| Total net sales | 87,641 | 90,796 | 31,145 | 28,968 | 27,528 | 30,956 | 28,677 | 28,407 |
| SEKm | 2109 | 2009 | 2021:3 | 2021:2 | 2021:1 | 2020:4 | 2020:3 | 2020:2 |
|---|---|---|---|---|---|---|---|---|
| Personal Care | 5,332 | 5,282 | 1,914 | 1,710 | 1,708 | 1,879 | 1,805 | 1,438 |
| Consumer Tissue | 3,834 | 6,110 | 942 | 1,207 | 1,685 | 1,935 | 1,894 | 2,124 |
| Professional Hygiene | 2,029 | 2,508 | 900 | 710 | 419 | 809 | 634 | 481 |
| Other | -592 | -666 | -170 | -218 | -204 | -231 | -214 | -261 |
| Total adjusted EBITA | 10,603 | 13,234 | 3,586 | 3,409 | 3,608 | 4,392 | 4,119 | 3,782 |
| SEKm | 2109 | 2009 | 2021:3 | 2021:2 | 2021:1 | 2020:4 | 2020:3 | 2020:2 |
|---|---|---|---|---|---|---|---|---|
| Personal Care | 4,741 | 4,705 | 1,682 | 1,531 | 1,528 | 1,690 | 1,614 | 1,241 |
| Consumer Tissue | 3,830 | 6,106 | 941 | 1,205 | 1,684 | 1,933 | 1,894 | 2,122 |
| Professional Hygiene | 2,022 | 2,479 | 898 | 709 | 415 | 801 | 624 | 472 |
| Other | -592 | -666 | -170 | -217 | -205 | -231 | -214 | -261 |
| Total adjusted operating profit1 | 10,001 | 12,624 | 3,351 | 3,228 | 3,422 | 4,193 | 3,918 | 3,574 |
| Financial items | -472 | -786 | -137 | -177 | -158 | -172 | -184 | -283 |
| Profit before tax1 | 9,529 | 11,838 | 3,214 | 3,051 | 3,264 | 4,021 | 3,734 | 3,291 |
| Income taxes | -2,430 | -3,061 | -808 | -849 | -773 | -993 | -1,049 | -823 |
| Net profit for the period2 | 7,099 | 8,777 | 2,406 | 2,202 | 2,491 | 3,028 | 2,685 | 2,468 |
| 1Excluding items affecting comparability before tax amounting to: | 444 | -57 | 524 | -136 | 56 | -2 | -101 | 61 |
| 2Excluding items affecting comparability after tax amounting to: | 493 | -59 | 559 | -127 | 61 | 1 | -85 | 40 |
| % | 2109 | 2009 | 2021:3 | 2021:2 | 2021:1 | 2020:4 | 2020:3 | 2020:2 |
|---|---|---|---|---|---|---|---|---|
| Personal Care | 15.7 | 15.3 | 15.8 | 15.3 | 15.9 | 16.1 | 16.2 | 13.5 |
| Consumer Tissue | 11.0 | 16.4 | 8.0 | 10.3 | 14.6 | 14.8 | 16.3 | 17.1 |
| Professional Hygiene | 10.9 | 13.1 | 12.4 | 11.6 | 8.0 | 13.0 | 10.7 | 9.0 |
| SEKm | 2021:3 | 2021:2 | 2021:1 | 2020:4 | 2020:3 |
|---|---|---|---|---|---|
| Net sales | 31,145 | 28,968 | 27,528 | 30,956 | 28,677 |
| Cost of goods sold | -22,202 | -20,149 | -18,660 | -20,820 | -19,389 |
| Items affecting comparability - cost of goods sold | -11 | -43 | -10 | 22 | -94 |
| Gross profit | 8,932 | 8,776 | 8,858 | 10,158 | 9,194 |
| Sales, general and administration | -5,361 | -5,446 | -5,272 | -5,777 | -5,181 |
| Items affecting comparability - sales, general and administration | 535 | -93 | 66 | -24 | -7 |
| Share of profits of associates and joint ventures | 4 | 36 | 12 | 33 | 12 |
| EBITA | 4,110 | 3,273 | 3,664 | 4,390 | 4,018 |
| Amortization of acquisition-related intangible assets | -235 | -181 | -186 | -199 | -201 |
| Operating profit | 3,875 | 3,092 | 3,478 | 4,191 | 3,817 |
| Financial items | -137 | -177 | -158 | -172 | -184 |
| Profit before tax | 3,738 | 2,915 | 3,320 | 4,019 | 3,633 |
| Income taxes | -773 | -840 | -768 | -990 | -1,033 |
| Net profit for the period | 2,965 | 2,075 | 2,552 | 3,029 | 2,600 |

| SEKm | 2109 | 2009 |
|---|---|---|
| Administrative expenses | -562 | -557 |
| Other operating income | 160 | 28 |
| Operating loss | -402 | -529 |
| Financial items | 3,639 | -824 |
| Profit before tax | 3,237 | -1,353 |
| Income taxes | 287 | 274 |
| Profit for the period | 3,524 | -1,079 |
| SEKm | September 30, 2021 | December 31, 2020 |
|---|---|---|
| Intangible assets | 0 | 0 |
| Property, plant and equipment | 14 | 14 |
| Financial non-current assets | 176,188 | 176,401 |
| Total non-current assets | 176,202 | 176,415 |
| Total current assets | 694 | 2,140 |
| Total assets | 176,896 | 178,555 |
| Restricted equity | 2,350 | 2,350 |
| Non-restricted equity | 84,972 | 86,189 |
| Total equity | 87,322 | 88,539 |
| Untaxed reserves | 5 | 5 |
| Provisions | 889 | 874 |
| Non-current liabilities | 36,163 | 31,710 |
| Current liabilities | 52,517 | 57,427 |
| Total equity, provisions and liabilities | 176,896 | 178,555 |

This interim report has been prepared in accordance with IAS 34 and recommendation RFR 1 of the Swedish Financial Reporting Board (RFR), and with regards to the Parent Company, RFR 2.
Effective January 1, 2021, Essity applies the following new and amended IFRS:
Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16
All other applied accounting principles and calculation methods correspond to those presented in Essity Aktiebolag's (publ) Annual and Sustainability Report for 2020.
Amendments were introduced due to the transition from Interbank Offered Rates (IBORs) to alternative benchmark interest rates. The amendments address issues that may arise when an existing interest rate benchmark is replaced with an alternative benchmark interest rate and describe how any effects resulting from the change of interest rate benchmark is to be recognized. The amendments also include disclosures related to the transition. Essity is monitoring all changes concerning the development of alternative interest rate benchmarks and is continuously evaluating the effects on the financial statements. The EU endorsed the amendments on January 13, 2021 and they came into effect on January 1, 2021.
The assessment is that the above amendments will not have any material effect on the Group's or the Parent Company's earnings or financial position.
Essity has previously recognized ProNARO as a joint operation according to the proportional method. ProNARO's principal task is to negotiate better prices and optimize inventory levels by pooling timber purchases. ProNARO has expanded its operations and now also sells to external customers other than Essity and Sappi (the other owner). This change of focus means that the company is more independent and Essity has thus made the assessment that the company is to be recognized according to the equity method as of January 1, 2021. This change means that Essity's participation in ProNARO's assets and liabilities is deconsolidated from the accounts. ProNARO's reported net sales amounted to SEK 435m and EBITA to SEK 0m in Essity's accounts for 2020.
Essity's Board of Directors determines the Group's strategic direction based on recommendations from the Executive Management Team. Responsibility for the long-term, overall management of strategic risks corresponds to the company's delegation structure, from the Board of Directors to the CEO and from the CEO to the business unit presidents. This means that most operational risks are managed by Essity's business units at the local level, but that they are coordinated when considered necessary. The tools used in this coordination consist primarily of the business units' regular reporting and the annual strategy process, where risks and risk management are a part of the process.
Essity's financial risk management is centralized, as is the Group's internal bank for the Group companies' financial transactions and management of the Group's energy risks. Financial risks are managed in accordance with the Group's finance policy, which is adopted by Essity's Board of Directors and which – together with Essity's energy risk policy – makes up a framework for risk management. Risks are aggregated and monitored on a regular basis to ensure compliance with these guidelines. Essity has also centralized other risk management.
Essity has a staff function for internal audit, which monitors compliance in the organization with the Group's policies.
Essity's risk exposure and risk management are described on pages 36–41 of Essity's Annual and Sustainability Report 2020. No significant changes have taken place that have affected the reported risks. This also relates to the uncertainty and risks that have arisen on account of the COVID-19 pandemic that may affect Essity's sales, earnings and financial position.
Risks in conjunction with company acquisitions are analyzed in the due diligence processes that Essity carries out prior to all acquisitions. In cases where acquisitions have been carried out that may affect the assessment of Essity's risk exposure, these are described under the heading "Events during the quarter" in the interim and year-end reports.

Distribution by level for measurement at fair value
| SEKm | Carrying amount in the balance sheet |
Measured at fair value through profit or loss |
Derivatives used for hedge accounting |
Measured at fair value through OCI |
Financial liabilities measured at amortized cost |
Of which fair value by level1 |
|
|---|---|---|---|---|---|---|---|
| September 30, 2021 | 1 | 2 | |||||
| Derivatives Non-current financial assets |
4,616 98 |
570 - |
4,046 - |
- 98 |
- - |
- 98 |
4,616 - |
| Total assets | 4,714 | 570 | 4,046 | 98 | 0 | 98 | 4,616 |
| Derivatives Financial liabilities Current financial liabilities Non-current financial liabilities Total liabilities |
693 14,622 48,967 64,282 |
252 28 20,454 20,734 |
441 - - 441 |
- - - - |
- 14,594 28,513 43,107 |
- - - - |
693 28 20,454 21,175 |
| December 31, 2020 | |||||||
| Derivatives | 1,650 | 571 | 1,079 | - | - | - | 1,650 |
| Non-current financial assets | 96 | - | - | 96 | - | 96 | - |
| Total assets | 1,746 | 571 | 1,079 | 96 | 0 | 96 | 1,650 |
| Derivatives Financial liabilities |
753 | 682 | 71 | - | - | - | 753 |
| Current financial liabilities | 7,895 | 5,038 | - | - | 2,857 | - | 5,038 |
| Non-current financial liabilities | 38,199 | 10,615 | - | - | 27,584 | - | 10,615 |
| Total liabilities | 46,847 | 16,335 | 71 | - | 30,441 | - | 16,406 |
1 No financial instruments have been classified to level 3
The total fair value of the above financial liabilities, excluding lease liabilities, is SEK 60,456m (43,947). The fair value of trade receivables, other current and non-current receivables, cash and cash equivalents, trade payables and other current and noncurrent liabilities is estimated to be equal to their carrying amount.
No transfers between level 1 and 2 were made during the period.
On May 14, Essity Aktiebolag acquired the remaining 25% of the shares of ABIGO Medical AB, making the company a wholly owned subsidiary. The purchase consideration paid for the remaining 25% amounted to SEK 228m. As per the terms of the transaction, ABIGO Medical's pharma business has been divested and sold to the company's founder Jan G. Smith on July 1.
On July 1, Essity acquired the remaining 63.8% of the shares in the hygiene company Asaleo Care. Up until June 30, Essity – with its holding of 36.2% of the shares – has been the largest shareholder of Asaleo Care, which prior to the acquisition was listed on the Australian Securities Exchange. Up until the acquisition of the remaining shares, Asaleo Care was recognized as an associate according to the equity method.
Essity has paid 1.40 cash per share, a total of AUD 486m. The consideration entails an implicit value for all shares, including the previous holding, of AUD 760m (approximately SEK 4.9bn) and assumed net debt amounts to approximately AUD 196m. Essity's previous holding in Asaleo Care of 36.2% has, according to IFRS, been remeasured on July 1, resulting in a positive extraordinary remeasurement effect of AUD 110m (SEK 706m) in the third quarter. The remeasurement effect was calculated on the basis of the cash offer, less the assessed control premium contained therein.
Since the acquisition, Asaleo Care's reported net sales amounted to SEK 749m, adjusted EBITDA to SEK 124m and adjusted EBITA to SEK 78m. Had Asaleo Care been consolidated as of January 1, 2021, net sales would have amounted to SEK 1,848m, adjusted EBITDA to SEK 322m and adjusted EBITA to SEK 193m.

| Purchase price allocation, Asaleo Care | Preliminary |
|---|---|
| SEKm | |
| Intangible assets | 1,822 |
| Non-current assets | 1,041 |
| Current assets | 1,092 |
| Cash and cash equivalents | 159 |
| Loan liabilities | -1,416 |
| Provisions and other non-current liabilities | -479 |
| Operating liabilities | -612 |
| Net identifiable assets and liabilities | 1,607 |
| Goodwill | 2,768 |
| Carrying amount of share in associate | -565 |
| Revaluation of previously owned share | -706 |
| Consideration transferred | 3,104 |
| Consideration transferred | -3,104 |
| Cash and cash equivalents in acquired operations | 159 |
| Effect on Group's cash and cash equivalents (Consolidated | |
| cash flow statement) | -2,945 |
| Acquired net debt excluding cash and cash equivalents | -1,416 |
| Acquisition of operation including assumed net debt | |
| (Consolidated operating cash flow statement) | -4,361 |
On August 31, 2021, Essity finalized the acquisition of 45.8% of the shares in the Colombian hygiene company Productos Familia S.A. ("Familia"). Essity now owns 95.8% of Familia. The purchase price amounted to USD 1,540m (approximately SEK 13bn) for 100% of the company on a debt-free basis. Already prior to acquisition of the additional shares, Essity had control of Familia and it was fully consolidated in the Group's accounts. The transaction with shareholders entailed an increase of SEK 5,960m in Essity's net debt and the corresponding decrease in Essity's equity.
Guidelines for Alternative Performance Measures (APMs) for companies with securities listed on a regulated market in the EU have been issued by ESMA (European Securities and Markets Authority). These guidelines are to be applied for APMs not supported under IFRS.
This interim report refers to a number of performance measures not defined in IFRS. These performance measures are used to help investors, management and other stakeholders analyze the company's operations. These non-IFRS measures may differ from similarly titled measures among other companies. Essity's 2020 Annual Report, pages 71–76, describes the various non-IFRS performance measures that are used as a complement to the financial information presented in accordance with IFRS. Tables are presented below that show how the performance measures have been calculated.
| SEKm | 2109 | 2012 |
|---|---|---|
| Total assets | 176,288 | 154,645 |
| -Financial assets | -12,945 | -9,530 |
| -Non-current non-interest bearing liabilities | -8,195 | -6,700 |
| -Current non-interest bearing liabilities | -34,228 | -32,385 |
| Capital employed | 120,920 | 106,030 |
| SEKm | 2021:3 | 2021:2 | 2021:1 | 2020:4 | 2020:3 |
|---|---|---|---|---|---|
| Personal Care | 45,126 | 42,165 | 42,644 | 40,505 | 43,268 |
| Consumer Tissue | 50,632 | 48,493 | 47,084 | 45,283 | 46,464 |
| Professional Hygiene | 24,595 | 22,305 | 22,607 | 20,915 | 22,221 |
| Other | 567 | -281 | -5,092 | -673 | -322 |
| Capital employed | 120,920 | 112,682 | 107,243 | 106,030 | 111,631 |

| SEKm | 2109 | 2012 |
|---|---|---|
| Inventories | 20,103 | 16,383 |
| Trade receivables | 19,126 | 17,825 |
| Other current receivables | 5,614 | 2,173 |
| Trade payables | -16,668 | -14,791 |
| Other current liabilities | -15,385 | -14,545 |
| Other | -228 | 101 |
| Working capital | 12,562 | 7,146 |
| SEKm | 2109 | 2012 |
|---|---|---|
| Surplus in funded pension plans | 1,763 | 2,817 |
| Non-current financial assets | 440 | 738 |
| Current financial assets | 642 | 993 |
| Cash and cash equivalents | 10,100 | 4,982 |
| Financial assets | 12,945 | 9,530 |
| Non-current financial liabilities | 49,193 | 38,202 |
| Provisions for pensions | 4,283 | 5,328 |
| Current financial liabilities | 15,020 | 8,688 |
| Financial liabilities | 68,496 | 52,218 |
| Net debt | 55,551 | 42,688 |
| SEKm | 2109 | 2009 | 2021:3 | 2020:3 |
|---|---|---|---|---|
| Operating profit | 10,445 | 12,567 | 3,875 | 3,817 |
| -Amortization of acquisition-related intangible assets | 602 | 610 | 235 | 201 |
| -Depreciation/amortization | 4,000 | 4,204 | 1,383 | 1,330 |
| -Depreciation right-of-use asset | 686 | 700 | 239 | 242 |
| -Impairment | 1 | 71 | 3 | 25 |
| -Items affecting comparability - impairment net | 101 | 186 | 72 | 116 |
| EBITDA | 15,835 | 18,338 | 5,807 | 5,731 |
| -Items affecting comparability excluding depreciation/amortization and impairment | -545 | -129 | -596 | -15 |
| Adjusted EBITDA | 15,290 | 18,209 | 5,211 | 5,716 |
| SEKm | 2109 | 2009 | 2021:3 | 2020:3 |
|---|---|---|---|---|
| Operating profit | 10,445 | 12,567 | 3,875 | 3,817 |
| -Amortization of acquisition-related intangible assets | 602 | 610 | 235 | 201 |
| -Operating profit before amortization of acquisition-related intangible assets | ||||
| (EBITA) | 11,047 | 13,177 | 4,110 | 4,018 |
| EBITA margin (%) | 12.6 | 14.5 | 13.2 | 14.0 |
| -Items affecting comparability - cost of goods sold | 64 | 203 | 11 | 94 |
| -Items affecting comparability - sales, general and administration | -508 | -146 | -535 | 7 |
| Adjusted EBITA | 10,603 | 13,234 | 3,586 | 4,119 |
| Adjusted EBITA margin (%) | 12.1 | 14.6 | 11.5 | 14.4 |

| SEKm | 2109 | 2009 | 2021:3 | 2020:3 |
|---|---|---|---|---|
| Personal Care | ||||
| Operating cash surplus | 6,644 | 6,715 | 2,375 | 2,261 |
| Change in working capital | -309 | -316 | 565 | 208 |
| Investment in non-current assets, net | -1,305 | -1,026 | -617 | -385 |
| Restructuring costs, etc. | -81 | 45 | -17 | -32 |
| Operating cash flow before investments in operating assets through leases | 4,949 | 5,418 | 2,306 | 2,052 |
| Investment in operating assets through leases | -10 | -66 | 12 | -36 |
| Operating cash flow | 4,939 | 5,352 | 2,318 | 2,016 |
| Consumer Tissue | ||||
| Operating cash surplus | 5,837 | 8,189 | 1,650 | 2,557 |
| Change in working capital | -729 | -954 | -46 | -1,135 |
| Investment in non-current assets, net | -2,538 | -1,854 | -887 | -749 |
| Restructuring costs, etc. | -128 | -236 | -64 | -149 |
| Operating cash flow before investments in operating assets through leases | 2,442 | 5,145 | 653 | 524 |
| Investment in operating assets through leases | -63 | -108 | -24 | -9 |
| Operating cash flow | 2,379 | 5,037 | 629 | 515 |
| Professional Hygiene | ||||
| Operating cash surplus | 3,549 | 4,123 | 1,436 | 1,160 |
| Change in working capital | -846 | -381 | 39 | 112 |
| Investment in non-current assets, net | -604 | -800 | -250 | -310 |
| Restructuring costs, etc. | -327 | -487 | -83 | -179 |
| Operating cash flow before investments in operating assets through leases | 1,772 | 2,455 | 1,142 | 783 |
| Investment in operating assets through leases | -14 | -41 | -10 | 0 |
| Operating cash flow | 1,758 | 2,414 | 1,132 | 783 |
| SEKm | 2109 | 2021:3 |
|---|---|---|
| Personal Care | ||
| Organic net sales | 1,545 | 945 |
| Exchange rate effect1 | -1,944 | -108 |
| Acquisition/Divestments | -1 | 160 |
| Recognized change | -400 | 997 |
| Consumer Tissue | ||
| Organic net sales | -485 | -65 |
| Exchange rate effect1 | -1,475 | 148 |
| Acquisition/Divestments | -199 | 53 |
| Recognized change | -2,159 | 136 |
| Professional Hygiene | ||
| Organic net sales | 421 | 1,226 |
| Exchange rate effect1 | -1,205 | -108 |
| Acquisition/Divestments | 198 | 212 |
| Recognized change | -586 | 1,330 |
| Essity | ||
| Organic net sales | 1,471 | 2,110 |
| Exchange rate effect1 | -4,625 | -67 |
| Acquisition/Divestments | -1 | 424 |
| Recognized change | -3,155 | 2,467 |
1Consists only of currency translation effects
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.